Project Grant HT94252410490
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$712K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
The Defense Health Agency has awarded a $178,000 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "DISSECTING THE DIFFERENCE IN THE PATHOGENESIS AND IMMUNE MICROENVIRONMENT OF PEDIATRIC AND ADULT OSTEOSARCOMA". This research project falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for the U.S. military and the public. DFCI, a non-profit hospital and cancer...
The Defense Health Agency has awarded a $1,780,000 Project Grant titled "SUPPORTING UNDERREPRESENTED POPULATIONS IN GENOMICS-BASED CANCER TRIAL ENROLLMENT (SURGE)" to the Dana-Farber Cancer Institute, Inc. in Boston, MA. This award, funded through the Military Medical Research and Development program (CFDA 12.420), will support cancer research focused on improving enrollment of underrepresented populations in genomics-based clinical trials. The grant period runs from July 1, 2024 to...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...